- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
MNOV
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
MediciNova Inc · Healthcare · Biotechnology
Latest close
1.33 USD
0.8%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -7.4% below the Trend Line and sits at 20.5% of its 52-week range. The latest completed week returned 0.8%, after a -7.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 53/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.
Setup score
26
out of 100
Latest Close
1.33 USD
31 Jul 2026
1W Return
0.8%
latest completed week
4W Return
-7.0%
short-term follow-through
12W Return
-5.0%
quarterly tape
Trend Breadth
30.8%
16 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.8%
Latest completed week; four-week move -7.0%.
Indicator stack
17/51
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 39.78%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
53/100 conviction; expected move 29.5%.
News sentiment
55/100
53 relevant articles in the latest sentiment read.
Event risk
11d
Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -7.4% below the Trend Line and sits at 20.5% of its 52-week range. The latest completed week returned 0.8%, after a -7.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0612-week average 0.18
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.06Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -7.0% over four weeks, -5.0% over 12 weeks, and -7.0% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year16
Trend breadth30.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.24Latest activity-pressure read.
Pressure change65.7%Four-week change in activity pressure.
Leadership-13.63Latest relative-leadership reading.
RS change-15.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 79%
Model confidence 76%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength52/100Blend of value, momentum, and quality. Underlying universe rank 49; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality49/100Profitability and accounting quality. Underlying universe rank 52; rank 1 is best.
Momentum50/100Medium-term price momentum. Underlying universe rank 51; rank 1 is best.
Growth50/100Revenue and earnings growth. Underlying universe rank 51; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 108.9x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -25.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 15.2% Gross profit retained from each unit of revenue.
- Operating margin
- -1963.3% Operating profit retained from revenue.
- Free-cash-flow margin
- -1588.9% Free cash flow generated from revenue.
- Return on invested capital
- -71.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 1/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.4% Net share repurchases relative to market value.
- Shareholder yield
- -0.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.3x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
MNOV shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.00, expected move of 29.5%, and Sharemaestro trend signal inactive.
Conviction53/100
Expected move29.5%
Put/call volume0.00
Insider activity3 / 0
3 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment55/100
Weighted news tone is neutral across 53 relevant articles.
12 positive · 37 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move29.5%Nearest-chain priced movement where available.
52-week drawdown-32.1%Distance below the 52-week high.
13-week volatility4.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher9 of 2615 weeks finished lower.
Best week+15.6%Week of 20 Mar.
Worst week-11.5%Week of 27 Mar.
Latest week+0.8%Week of 31 Jul.
Shape of recent returns
Strong gains4
Modest gains5
Flat weeks2
Modest losses9
Sharp losses6
Recent vol4.0%13-week weekly-return volatility.
Base vol8.0%52-week weekly-return volatility.
Up/down split20/28Count of positive and negative weeks in the 52-week window.
Average skew7.1% / -4.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape26/100
Trend, activity pressure, participation, and risk combine to a 26/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.06; No reversal markers Next-Week ExpectancyNegative 39.78%Next-week expectancy is negative with a 39.78% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors49/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 75; Small Cap Core rank 54 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options36/100MNOV shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.00, expected move of 29.5%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 29.5% Sentiment55/100Weighted news tone is neutral across 53 relevant articles.
Price to book forward of MediciNova, Inc. – NASDAQ:MNOV Insiders3 / 03 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 1.33 USD | 0.8% | 1.44 USD | 1.56 USD | -0.24 | -13.63 | 165.3K | Off |
| 24 Jul 2026 | 1.32 USD | -2.2% | 1.44 USD | 1.57 USD | -0.14 | -14.29 | 111.1K | Off |
| 17 Jul 2026 | 1.35 USD | -2.9% | 1.43 USD | 1.57 USD | -0.30 | -14.22 | 312.9K | Off |
| 10 Jul 2026 | 1.39 USD | -2.8% | 1.44 USD | 1.58 USD | -0.44 | -15.54 | 179.1K | Off |
| 3 Jul 2026 | 1.43 USD | 8.3% | 1.44 USD | 1.59 USD | -0.69 | -11.82 | 499.4K | Off |
| 26 Jun 2026 | 1.32 USD | 0.0% | 1.45 USD | 1.59 USD | -1.08 | -18.08 | 461.9K | Off |
| 19 Jun 2026 | 1.32 USD | 7.3% | 1.45 USD | 1.60 USD | -1.03 | -22.14 | 298.4K | Off |
| 12 Jun 2026 | 1.23 USD | -6.1% | 1.45 USD | 1.61 USD | -1.02 | -25.93 | 214.1K | Off |
| 5 Jun 2026 | 1.31 USD | -3.7% | 1.47 USD | 1.61 USD | -1.00 | -19.84 | 92.0K | Off |
| 29 May 2026 | 1.36 USD | -2.9% | 1.47 USD | 1.62 USD | -0.94 | -21.06 | 199.9K | Off |
| 22 May 2026 | 1.40 USD | 1.4% | 1.48 USD | 1.63 USD | -0.95 | -16.97 | 83.4K | Off |
| 15 May 2026 | 1.38 USD | -1.4% | 1.47 USD | 1.63 USD | -1.00 | -17.72 | 96.0K | Off |
| 8 May 2026 | 1.40 USD | 0.0% | 1.47 USD | 1.64 USD | -0.86 | -17.19 | 100.7K | Off |
| 1 May 2026 | 1.40 USD | 2.2% | 1.46 USD | 1.64 USD | -0.64 | -13.38 | 126.1K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.